This is a confident step forward for the company and it does bode well for an optimistic medium to long-term outlook, however, in all honesty, there is a board of directors and a CEO that could well and truly have much these responsibilities under their remit, namely Nathan Buzza who was appointed recently and ticks a majority of the requirements.
He is constantly posting away about Alcidion on Twitter, yet was silent on what was a fairly significant announcement recently to boost SH confidence in the company and the pending US trials. Do better ResApp. He is no longer a director of Alcidion, he is, however, a director of ResApp.
RAP Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
